A Phase 1b/2 Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single
Agent and In Combination with Enzalutamide in Subjects with
Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to study the effects of the investigational drug GS-5829 alone and in combination with the standard of care prostate cancer treatment enzalutamide on metastatic castrate resistant prostate cancer (advanced stage prostate cancer).
Metastatic castration-resistant prostate cancer
Prostate cancer that has spread to other parts of your body (metastatic)
Castration-resistant (your cancer has stopped responding to hormonal therapy)
You are in generally good health aside from your cancer
18 - 100
Healthy Volunteers Needed
Duration of Participation
You will receive the study drug(s) for as long as your cancer does not worsen, you do not experience unacceptable side effects, and you do not withdraw your consent or decide you no longer wish to participate. After you stop taking the study drug(s) you will be followed via phone call every 3 months to see how you are doing until the study is ended.
Knight Clinical Trials Information Line
Phone 503-494-1080 or firstname.lastname@example.org
Gilead Sciences, Inc.